PRESS RELEASE published on 11/25/2025 at 18:33, 3 months 22 days ago Inside Information / Other news releases ABIONYX Pharma reports €3.06 million revenue and €2.8 million cash position as of Q3 2025. Expands focus on sepsis and rare diseases Revenue Cash Position ABIONYX Pharma Sepsis Q3 2025
BRIEF published on 11/12/2025 at 07:05, 4 months 5 days ago ABIONYX Pharma is in advanced discussions with the IHU SEPSIS Strategic Partnership Biopharmaceuticals ABIONYX Pharma Sepsis IHU SEPSIS
BRIEF published on 10/21/2025 at 18:54, 4 months 27 days ago Genetic validation of ApoA-I in sepsis by ABIONYX Pharma Innovative Therapies ABIONYX Pharma Sepsis Apolipoprotein AI Genetic Validation
PRESS RELEASE published on 10/21/2025 at 18:49, 4 months 27 days ago Inside Information / Other news releases ABIONYX Pharma announces groundbreaking genetic validation study published in NATURE confirming Apolipoprotein A-I (ApoA-I) causality in Sepsis, reshaping critical care medicine ABIONYX Pharma Sepsis Genetic Validation Study NATURE Publication Apolipoprotein A-I
BRIEF published on 10/06/2025 at 15:00, 5 months 11 days ago Threshold crossing by the Caisse des dépôts et consignations in ABIONYX PHARMA Voting Rights CDC Threshold Crossing Bpifrance ABIONYX
BRIEF published on 10/06/2025 at 14:56, 5 months 11 days ago Threshold Crossing by Bpifrance at ABIONYX PHARMA Voting Rights Actions Threshold Crossing Bpifrance ABIONYX Pharma
BRIEF published on 09/25/2025 at 20:21, 5 months 22 days ago ABIONYX Pharma: Financial results for the first half of 2025 Financial Results Research And Development Treasury France 2030 Plan ABIONYX Pharma
PRESS RELEASE published on 09/25/2025 at 20:16, 5 months 22 days ago Inside Information / News release on accounts, results ABIONYX Pharma announces its 2025 half-year financial results, including revenue of €2.1 million and ongoing initiatives in biotech innovation. Company receives government support for sepsis research Revenue Biotech Innovation ABIONYX Pharma 2025 Financial Results Sepsis Research
BRIEF published on 08/28/2025 at 18:56, 6 months 20 days ago ABIONYX Pharma 2025 half-year review Treasury Financial Support Turnover ABIONYX Pharma Semester 2025
PRESS RELEASE published on 08/28/2025 at 18:51, 6 months 20 days ago Inside Information / Other news releases ABIONYX Pharma provided an update on its activity and cash position for Q2 2025. Company's revenue, cash position, and government funding details revealed Revenue Cash Position Update Government Funding ABIONYX Pharma
Published on 03/17/2026 at 21:30, 20 minutes ago Rainy Mountain Announces Appointment of Colton Griffith to Board of Directors
Published on 03/17/2026 at 13:30, 8 hours 20 minutes ago Hillcrest Energy Technologies Confirms ZVS PCS1000 Prototype on Track for June 2026
Published on 03/17/2026 at 13:30, 8 hours 20 minutes ago Namibia Critical Metals Welcomes Toyota Tsusho as Strategic Partner in the Lofdal Heavy Rare Earths Project
Published on 03/17/2026 at 13:00, 8 hours 50 minutes ago Avant Brands Announces Strategic Realignment of European Operations and Reclaims BLK MKT Brand Rights in Germany and Switzerland
Published on 03/17/2026 at 21:21, 29 minutes ago KION GROUP AG successfully places a bond of € 500 million
Published on 03/17/2026 at 20:55, 55 minutes ago EQS-Adhoc: thyssenkrupp nucera lowers its sales and EBIT outlook for the Group and the gH2 segment for FY 2025/26 due to higher project costs
Published on 03/17/2026 at 17:58, 3 hours 52 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/17/2026 at 07:00, 14 hours 50 minutes ago Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 1 day 3 hours ago Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 1 day 3 hours ago Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 1 day 3 hours ago Reporting on share buyback transactions carried out between March 9 and March 13, 2026
